KBC

MICLEDI Microdisplays BV is a Belgium-based company that specializes in the design and manufacture of micro light emitting diode (LED) display chips for augmented reality (AR) glasses. As a fabless developer, MICLEDI focuses on innovative technologies that combine III/V materials processing with 3D integration and 300mm silicon-based processing. The company aims to deliver high-quality, power-efficient AR displays by utilizing a proprietary ASIC, which allows for the creation of compact and self-contained display modules. Serving the semiconductor industry, MICLEDI is positioned at the forefront of microLED technology, contributing to the advancement of augmented reality applications.

ArtiQ is an innovative spin-off company from the University of Leuven, established in early 2019 by founders with extensive backgrounds in respiratory medicine, medical devices, and artificial intelligence. The company focuses on enhancing the diagnosis, treatment, and management of respiratory diseases through advanced technology. ArtiQ has developed AI-based software that automates the interpretation of pulmonary function tests, enabling medical professionals to accurately and efficiently detect disease patterns and assess lung function. This technology not only aids in the early identification of lung diseases but also provides healthcare practitioners with recommendations on subsequent patient care actions. ArtiQ aims to serve as a trusted partner for medical practitioners in the respiratory field, positively impacting patients, doctors, and the healthcare system.

Interlease is a Bulgarian lease company owned by KBC Group, a Belgian banking and insurance entity. The company specializes in enhancing the competitiveness and market positions of Bulgarian enterprises both domestically and internationally. Interlease finances the acquisition of high-quality equipment, transportation vehicles, cars, and office equipment. It offers professional after-sales service utilizing effective internet and mobile technologies, ensuring clients can select their suppliers and asset types to best suit their business needs.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.

Aristo Music NV develops selection and distribution techniques and technologies for digital music and provides music related services. The company also develops various Internet applications, which include a Web radio that consists of a musical database. It serves catering, retail, business, leisure, and government markets. The company is based in Heverlee, Belgium.

Okapi Sciences NV is a Belgium-based company focused on developing antiviral therapeutics specifically for pets and livestock. It has a proprietary platform that supports the creation of innovative treatments targeting various viral diseases. The company is advancing its pipeline of clinical and development stage candidates, including drugs intended for feline herpes and feline immunodeficiency virus. Through its research and development efforts, Okapi aims to provide veterinarians with the latest antiviral treatments, enhancing the standards of care for animal health. Targeting both companion animals and livestock, Okapi Sciences is positioned to make significant contributions to veterinary medicine with its novel technologies and strong academic partnerships.

Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. Founded in 2006 and headquartered in Turnhout, Belgium, Movetis focuses on conditions such as severe chronic constipation, ascites, pediatric reflux, and complex GI motility disorders like refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is specifically developed for the symptomatic treatment of chronic constipation in women, with ongoing research to extend its use to males, children, and conditions like opioid-induced constipation and postoperative ileus. Movetis is also advancing other candidates in its pipeline, including M0002, currently in Phase II trials for ascites, and M0003, which is entering Phase II development for treating heartburn and pediatric reflux in patients resistant to proton pump inhibitors. Additionally, the company has prioritized compounds from its preclinical portfolio and maintains partnerships with several academic institutions in Belgium and the Netherlands to enhance its research capabilities.

Pronota NV is a Belgian company focused on developing and commercializing innovative diagnostics aimed at the early detection of life-threatening conditions and addressing unmet medical needs. Established in 2004 and based in Zwijnaarde, the company specializes in non-invasive, validated protein biomarker diagnostics. Its portfolio includes tests for conditions such as heart failure, pre-eclampsia, and sepsis, among others. Pronota is dedicated to enhancing patient care through its proprietary diagnostic solutions. The company benefits from a strong network of investors and key opinion leaders in the medical field, reflecting its commitment to advancing diagnosis and personalized healthcare. Pronota was previously known as Peakadilly NV until its name change in November 2006.